Co-Diagnostics JV Expands South Asia Distribution, Tapping $13B Market
CODX sits 26% above its 52-week low of $2.05 on elevated volume (54× avg).
Summary
Co-Diagnostics' Indian joint venture, CoSara Diagnostics Pvt. Ltd., has significantly expanded its commercial and distribution territory across South Asia to include Bangladesh, Pakistan, Nepal, and Sri Lanka. This move is estimated to increase its addressable market by $13.0 billion, a highly material development for Co-Diagnostics given its relatively small market capitalization. This expansion supports the planned commercialization of the CoSara PCR Pro(R) point-of-care platform and SARAGENE(R) product line, positioning the company for substantial growth in molecular diagnostics. Investors should monitor regulatory approvals in these new territories and the subsequent commercialization efforts.
At the time of this announcement, CODX was trading at $2.59 on OTC in the Life Sciences sector, with a market capitalization of approximately $5.4M. The 52-week trading range was $2.05 to $46.50. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: FinanceWire.